Evidence for Clinical Implementation of Pharmacogenomics in Cardiac Drugs.

Objective: To comprehensively assess the pharmacogenomic evidence of routinely used drugs for clinical utility.

Methods: Between January 2, 2011, and May 31, 2013, we assessed 71 drugs by identifying all drug/genetic variant combinations with published clinical pharmacogenomic evidence. Literature supporting each drug/variant pair was assessed for study design and methods, outcomes, statistical significance, and clinical relevance.